Biotech Industry · global
Finding New Drug Targets in Disease Differences: AstraZeneca Teams Up with insitro on Hepatitis and Cardiomyopathy
The companies are launching an AI drug discovery collaboration with a $40 million upfront payment, focusing on the biological mechanisms underlying MASH and cardiomyopathy. The central test of the deal is whether insights from human and cellular data can be translated into verifiable therapeutic targets.
The same diagnosis may encompass different disease mechanisms. In drug development, choosing where to intervene often sets the direction before a molecule capable of acting there is found. AstraZeneca and insitro announced a collaboration on October 15 to use artificial intelligence to discover new targets and potential therapies for metabolic dysfunction-associated steatohepatitis (MASH) and cardiomyopathy, seeking starting points for drug development in biological differences among patients.
Under the terms disclosed by insitro, the company will receive a $40 million upfront payment and is eligible for up to approximately $1.46 billion in potential discovery, development and commercial milestone payments, as well as single-digit percentage royalties on future global sales. These subsequent payments depend on the corresponding conditions being met and cannot be considered revenue already secured. AstraZeneca will obtain exclusive worldwide rights to selected programs within the collaboration.
The collaboration has a clear division of responsibilities: insitro will use its Virtual Human platform to study the disease biology of both conditions and advance targets nominated by AstraZeneca from discovery through development candidate selection. AstraZeneca will lead subsequent clinical development, regulatory submissions and commercialization. The companies have not yet disclosed specific target names, the number of programs or a timeline for entering human trials.
The role of AI here is to help researchers understand disease and select targets. AstraZeneca said the platform integrates large-scale human and cellular data to support target identification and drug design. insitro emphasized that MASH and cardiomyopathy share a common challenge: patients with the same diagnosis may have different underlying biological mechanisms. The collaboration aims to identify factors within complex data that truly drive disease progression and may also be suitable for drug intervention.
However, identifying disease-causing factors remains a research and development objective for the platform at this stage. The companies’ collaboration announcements did not provide the sample size, patient composition, independent validation results or any clinical efficacy data generated by the collaboration. Whether associations in the data can support causal conclusions will still need to be established through subsequent experiments and drug research.
The deal connects an AI platform with a major pharmaceutical company’s development capabilities along a shared drug development path, while tying most potential compensation to future results. The next substantive advance will be the disclosure of specific targets and drug candidates, along with evidence supporting their mechanisms of action. For patients, new treatment options still lie beyond hurdles including safety, efficacy and regulatory review.